{"id":"placebo-of-pioglitazone","safety":{"commonSideEffects":[{"rate":null,"effect":"Placebo effect / nocebo effects (variable)"}]},"_chembl":{"chemblId":"CHEMBL595","moleculeType":"Small molecule","molecularWeight":"356.45"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a placebo of pioglitazone, this formulation is designed to be indistinguishable from the active drug but contains no active ingredient. It serves as a control comparator in a Phase 3 randomized controlled trial to assess the efficacy and safety of pioglitazone relative to no pharmacological intervention. The actual pioglitazone mechanism (thiazolidinedione insulin sensitizer) is not present in this placebo formulation.","oneSentence":"This is a placebo control arm in a clinical trial and contains no active pharmaceutical ingredient.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:11.768Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in Phase 3 clinical trial of pioglitazone (indication dependent on parent trial)"}]},"trialDetails":[{"nctId":"NCT06164665","phase":"PHASE4","title":"Effects of Pioglitazone on Exogenous Carbohydrate Oxidation During Steady-State Exercise at High Altitude","status":"COMPLETED","sponsor":"United States Army Research Institute of Environmental Medicine","startDate":"2023-03-01","conditions":"High Altitude","enrollment":9},{"nctId":"NCT07053319","phase":"PHASE1","title":"SGLT2i, Pioglitazone, and Ketone Production in T2D","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2026-07-20","conditions":"Type 2 Diabetes","enrollment":64},{"nctId":"NCT07391267","phase":"NA","title":"Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2026-02-01","conditions":"Chronic Kidney Diseases, MAFLD","enrollment":90},{"nctId":"NCT03866408","phase":"EARLY_PHASE1","title":"Insulin Regulation of Lipolysis and Lipolysis Proteins","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-11-12","conditions":"Obesity","enrollment":64},{"nctId":"NCT05705492","phase":"PHASE2","title":"Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2024-07-17","conditions":"Advanced Malignant Solid Neoplasm, Advanced Biliary Tract Carcinoma, Advanced Esophageal Carcinoma","enrollment":66},{"nctId":"NCT05305287","phase":"PHASE4","title":"Quantifying Hepatic Mitochondrial Fluxes in Humans","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2022-11-01","conditions":"Non-Alcoholic Fatty Liver Disease, Type 2 Diabetes, Mitochondrial Metabolism Disorders","enrollment":60},{"nctId":"NCT01026194","phase":"PHASE3","title":"Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-12","conditions":"Type 2 Diabetes Mellitus","enrollment":204},{"nctId":"NCT05028140","phase":"PHASE3","title":"Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus","status":"RECRUITING","sponsor":"EMS","startDate":"2024-10-08","conditions":"Type II Diabetes","enrollment":480},{"nctId":"NCT06571591","phase":"PHASE3","title":"Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celltrion","startDate":"2024-08-27","conditions":"T2DM","enrollment":582},{"nctId":"NCT06446531","phase":"PHASE1","title":"Prevention of Progression of Prediabetes, Obesity and CV Risk","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2024-09-11","conditions":"Pre-Diabetes, Weight, Body, Cardiovascular Diseases","enrollment":64},{"nctId":"NCT07056699","phase":"PHASE3","title":"SGLT2i, Pioglitazone, and Ketone Production in T1D","status":"NOT_YET_RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2026-01-30","conditions":"Type1diabetes","enrollment":24},{"nctId":"NCT04843046","phase":"PHASE2","title":"Pioglitazone as an Adjunct to Cognitive-Behavioral Therapy for Cocaine Relapse Prevention","status":"RECRUITING","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2021-08-23","conditions":"Cocaine Use Disorder","enrollment":60},{"nctId":"NCT04370093","phase":"PHASE4","title":"Pathogenesis of Uric Acid Nephrolithiasis: Role of Pioglitazone/Weight Loss","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2019-10-17","conditions":"Nephrolithiasis, Uric Acid","enrollment":29},{"nctId":"NCT06922656","phase":"PHASE4","title":"Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration?","status":"NOT_YET_RECRUITING","sponsor":"Dasman Diabetes Institute","startDate":"2025-09-15","conditions":"Type 1 Diabetes","enrollment":60},{"nctId":"NCT05107765","phase":"PHASE1, PHASE2","title":"Effects of Pioglitazone on Stress Reactivity and Alcohol Craving","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2022-05-12","conditions":"Alcohol Use Disorder","enrollment":67},{"nctId":"NCT05919147","phase":"PHASE2","title":"The Neuroendocrine Effects of Pioglitazone in Patients With Cancer and Cachexia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pennington Biomedical Research Center","startDate":"2024-01-03","conditions":"Lung Cancer","enrollment":24},{"nctId":"NCT06336798","phase":"PHASE2","title":"Bioenergetic Effect of Pioglitazone in CLD-PH","status":"RECRUITING","sponsor":"Emory University","startDate":"2024-12-17","conditions":"Pulmonary Hypertension, Pulmonary Hypertension Due to Lung Diseases","enrollment":20},{"nctId":"NCT03878459","phase":"PHASE4","title":"Dapagliflozin Plus Pioglitazone in T1DM","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2019-08-08","conditions":"Type 1 Diabetes Mellitus","enrollment":120},{"nctId":"NCT03864146","phase":"NA","title":"Pioglitazone for the Treatment of Alcohol Use Disorder","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2019-07-17","conditions":"Alcohol Use Disorder","enrollment":201},{"nctId":"NCT03471117","phase":"PHASE4","title":"Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients","status":"RECRUITING","sponsor":"The University of Texas at Arlington","startDate":"2018-04-01","conditions":"Chronic Kidney Diseases","enrollment":28},{"nctId":"NCT01225081","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Pioglitazone in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-09-15","conditions":"Type 2 Diabetes Mellitus","enrollment":152},{"nctId":"NCT05946564","phase":"PHASE3","title":"A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO Trial","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-10-24","conditions":"ANCA Associated Vasculitis, Rapidly Progressive Glomerulonephritis, Crescentic Glomerulonephritis","enrollment":126},{"nctId":"NCT04501406","phase":"PHASE2","title":"Low-Dose Pioglitazone in Patients With NASH (AIM 2)","status":"RECRUITING","sponsor":"University of Florida","startDate":"2020-12-15","conditions":"Type 2 Diabetes Mellitus (T2DM), Nonalcoholic Steatohepatitis","enrollment":166},{"nctId":"NCT05659459","phase":"PHASE2","title":"The KIN-FAST Trial (KIN001 For Accelerated Symptoms Termination) in Non Hospitalized Patients Infected With SARS-CoV-2","status":"TERMINATED","sponsor":"Kinarus AG","startDate":"2022-08-25","conditions":"COVID-19","enrollment":17},{"nctId":"NCT01028963","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-01","conditions":"Type 2 Diabetes Mellitus","enrollment":159},{"nctId":"NCT00179400","phase":"PHASE4","title":"The Role of Acute Combined PPAR Alpha and Gamma Stimulation on Insulin Action in Humans","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2000-12","conditions":"Type 2 Diabetes Mellitus","enrollment":26},{"nctId":"NCT02278562","phase":"PHASE2","title":"Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2014-10-22","conditions":"ESRD","enrollment":33},{"nctId":"NCT00904046","phase":"NA","title":"Pathophysiology of Uric Acid Nephrolithiasis","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2010-01-15","conditions":"Uric Acid Kidney Stone Disease","enrollment":172},{"nctId":"NCT04227093","phase":"PHASE4","title":"Acetazolamide Add-On Therapy to OSA Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2020-01-22","conditions":"Obstructive Sleep Apnea","enrollment":26},{"nctId":"NCT05394142","phase":"PHASE2","title":"A Clinical Trial to Evaluate the Efficacy, Tolerability, and Safety of a Fixed Dose Combination of Spironolactone, Pioglitazone & Metformin (SPIOMET) in Polycystic Ovary Syndrome (PCOS)","status":"RECRUITING","sponsor":"Fundació Sant Joan de Déu","startDate":"2022-05-24","conditions":"Polycystic Ovary Syndrome (PCOS)","enrollment":364},{"nctId":"NCT05775380","phase":"PHASE4","title":"The Role of Pioglitazone in Vascular Transcriptional Remodeling","status":"UNKNOWN","sponsor":"University of Campinas, Brazil","startDate":"2023-06-15","conditions":"Myocardial Reperfusion Injury","enrollment":20},{"nctId":"NCT01686711","phase":"PHASE4","title":"A Double-blind, Parallel Group, Comparative Study of Coadministration AD-4833 and SYR-322","status":"COMPLETED","sponsor":"Takeda","startDate":"2012-09","conditions":"Diabetes Mellitus","enrollment":207},{"nctId":"NCT05098327","phase":"PHASE3","title":"Pioglitazone and Insulin Resistance in ADT","status":"WITHDRAWN","sponsor":"State University of New York at Buffalo","startDate":"2021-08-01","conditions":"Prostate Cancer, Insulin Resistance, Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT04995978","phase":"PHASE2","title":"Insulin Resistance and Androgen Deprivation Therapy","status":"WITHDRAWN","sponsor":"St. Louis University","startDate":"2021-12-01","conditions":"Prostate Cancer, Insulin Resistance","enrollment":""},{"nctId":"NCT05875675","phase":"PHASE2","title":"Effects of Pioglitazone in Calcific Aortic Valve Disease","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2023-07-01","conditions":"Calcification of Aortic Valve, Aortic Valve Stenosis","enrollment":100},{"nctId":"NCT04885712","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or 30mg Add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2021-05-28","conditions":"Type2 Diabetes","enrollment":378},{"nctId":"NCT04658849","phase":"EARLY_PHASE1","title":"Insulin Resistance Following ADT for Prostate CA","status":"WITHDRAWN","sponsor":"St. Louis University","startDate":"2020-12-02","conditions":"Insulin Resistance, Prostate Cancer","enrollment":""},{"nctId":"NCT02535832","phase":"PHASE1","title":"Skeletal Muscle Dysfunction in Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2015-09","conditions":"Rheumatoid Arthritis, Insulin Resistance","enrollment":16},{"nctId":"NCT00203996","phase":"PHASE4","title":"Polycystic Ovary Syndrome (PCOS) and Sleep Apnea","status":"TERMINATED","sponsor":"University of Chicago","startDate":"2003-09","conditions":"Polycystic Ovary Syndrome, Obstructive Sleep Apnea","enrollment":37},{"nctId":"NCT02917629","phase":"PHASE2","title":"ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-05-31","conditions":"Oral Cavity Neoplasm, Oropharyngeal Neoplasm, Stage 0 Oral Cavity Squamous Cell Carcinoma American Joint Committee on Cancer (AJCC) v6 and v7","enrollment":6},{"nctId":"NCT00843791","phase":"NA","title":"Ghrelin Regulation and Structure: Effect of Thiazolidinedione Therapy on Ghrelin","status":"TERMINATED","sponsor":"Oregon Health and Science University","startDate":"2009-02","conditions":"Obesity, Insulin Resistance","enrollment":6},{"nctId":"NCT00297063","phase":"PHASE3","title":"BRL49653C In Type 2 Diabetes -Comparison Study With Pioglitazone And Placebo By Monotherapy-","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-01-11","conditions":"Diabetes Mellitus, Type 2","enrollment":350},{"nctId":"NCT05422092","phase":"NA","title":"Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2022-09-20","conditions":"Type 2 Diabetes Mellitus With Complication","enrollment":80},{"nctId":"NCT04123067","phase":"PHASE1, PHASE2","title":"Pioglitazone Treatment for Hyperglycemic Acute Ischemic Stroke","status":"TERMINATED","sponsor":"Milton S. Hershey Medical Center","startDate":"2020-09-01","conditions":"Stroke, Acute, Hyperglycemia, Diabetes","enrollment":1},{"nctId":"NCT05513729","phase":"","title":"Effect of Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2022-08-18","conditions":"Type 2 Diabetes Mellitus With Complication","enrollment":80},{"nctId":"NCT01161394","phase":"PHASE4","title":"Effect of Pioglitazone on Oxidative Load, Inflammatory End-Points and Vascular Reactivity in Obese Non-Diabetic Patients: A Dose Ranging Study","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"","conditions":"Inflammation","enrollment":24},{"nctId":"NCT00745225","phase":"PHASE4","title":"Peroxisome Proliferator-Activated Receptor-Gamma Activation in Peritoneal Dialysis Patients","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2006-02","conditions":"End-stage Renal Disease","enrollment":160},{"nctId":"NCT02338999","phase":"PHASE1, PHASE2","title":"Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)","status":"COMPLETED","sponsor":"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","startDate":"2015-06-18","conditions":"Systemic Lupus Erythematosus","enrollment":88},{"nctId":"NCT00484198","phase":"PHASE3","title":"Study of Rivoglitazone in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2007-04-23","conditions":"Type 2 Diabetes Mellitus","enrollment":1912},{"nctId":"NCT00571519","phase":"PHASE3","title":"Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus","status":"TERMINATED","sponsor":"Daiichi Sankyo","startDate":"2007-11-14","conditions":"Type 2 Diabetes Mellitus","enrollment":94},{"nctId":"NCT00720577","phase":"EARLY_PHASE1","title":"Study to Evaluate the Effect of Simvastatin, Losartan and Pioglitazone on Patients With Peripheral Arterial Disease.","status":"COMPLETED","sponsor":"Medtronic Endovascular","startDate":"2005-12","conditions":"Peripheral Arterial Disease","enrollment":164},{"nctId":"NCT00143520","phase":"PHASE2, PHASE3","title":"Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2004-12","conditions":"Type 2 Diabetes","enrollment":441},{"nctId":"NCT01748994","phase":"NA","title":"Cellular Dynamics of Subcutaneous Fat Distribution in Obese Women","status":"COMPLETED","sponsor":"Pennington Biomedical Research Center","startDate":"2011-02","conditions":"Obesity, Metabolic Syndrome","enrollment":63},{"nctId":"NCT03910361","phase":"PHASE4","title":"Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2019-04-12","conditions":"Type2 Diabetes, Non-Alcoholic Fatty Liver Disease","enrollment":51},{"nctId":"NCT04662866","phase":"PHASE2","title":"Effects of Glucose Lowering Agents in South Asian Women With Impaired Glucose Tolerance or Impaired Fasting Glucose","status":"UNKNOWN","sponsor":"Oslo University Hospital","startDate":"2021-02-10","conditions":"Impaired Glucose Tolerance, Insulin Sensitivity, Glucose Metabolism Disorders","enrollment":64},{"nctId":"NCT04604223","phase":"PHASE4","title":"Effect of Pioglitazone on T2DM Patients With COVID-19","status":"UNKNOWN","sponsor":"Dasman Diabetes Institute","startDate":"2021-01-18","conditions":"Covid19, Type 2 Diabetes","enrollment":1506},{"nctId":"NCT02697617","phase":"PHASE2","title":"Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease","status":"COMPLETED","sponsor":"Indiana University","startDate":"2016-01-26","conditions":"Polycystic Kidney Disease","enrollment":18},{"nctId":"NCT00099853","phase":"PHASE3","title":"Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-05","conditions":"Diabetes Mellitus, Type 2","enrollment":362},{"nctId":"NCT03860753","phase":"PHASE1, PHASE2","title":"Effects of Pioglitazone on Stress Reactivity and Alcohol Craving (Pilot)","status":"TERMINATED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2019-03-01","conditions":"Alcohol Use Disorder","enrollment":4},{"nctId":"NCT03452267","phase":"PHASE2, PHASE3","title":"Insulin Signaling in Skeletal Muscle","status":"WITHDRAWN","sponsor":"Wayne State University","startDate":"2019-09-01","conditions":"Insulin Sensitivity","enrollment":""},{"nctId":"NCT01068444","phase":"PHASE2","title":"The Efficacy and Safety of Pioglitazone in Patients With Nonalcoholic Steatohepatitis","status":"COMPLETED","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2009-04","conditions":"Hepatitis","enrollment":90},{"nctId":"NCT04113889","phase":"PHASE2","title":"Effects of Triple Drug Cocktail Therapy on Metabolic, Endocrine Alterations and Perceived Stress in Patients With Poly Cystic Ovary Syndrome","status":"COMPLETED","sponsor":"Khyber Medical University Peshawar","startDate":"2019-10-15","conditions":"PCOS","enrollment":147},{"nctId":"NCT01931566","phase":"PHASE3","title":"Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset","status":"TERMINATED","sponsor":"Takeda","startDate":"2013-08-01","conditions":"Mild Cognitive Impairment Due to Alzheimer's Disease","enrollment":3494},{"nctId":"NCT00694759","phase":"NA","title":"Cortisol Regulation in Polycystic Ovary Syndrome (PCOS)","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2006-10","conditions":"Polycystic Ovary Syndrome","enrollment":37},{"nctId":"NCT02284906","phase":"PHASE3","title":"AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease","status":"TERMINATED","sponsor":"Takeda","startDate":"2015-02-12","conditions":"Mild Cognitive Impairment Due to Alzheimer's Disease","enrollment":40},{"nctId":"NCT00094757","phase":"PHASE3","title":"An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (MK0431-023)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-10-06","conditions":"Diabetes Mellitus, Type 2","enrollment":521},{"nctId":"NCT00780234","phase":"PHASE2","title":"Pioglitazone for Lung Cancer Chemoprevention","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2009-08","conditions":"Lung Cancer, Endobronchial Dysplasia","enrollment":92},{"nctId":"NCT02231021","phase":"PHASE4","title":"The Practical Evidence of Antidiabetic Combination Therapy in Korea","status":"COMPLETED","sponsor":"Kun-Ho Yoon","startDate":"2014-09","conditions":"Type 2 Diabetes Mellitus","enrollment":216},{"nctId":"NCT03794518","phase":"PHASE3","title":"Effect of Dapagliflozin Plus Low Dose Pioglitazone on Hospitalization Rate in Patients With HF and HFpEF","status":"UNKNOWN","sponsor":"Hamad Medical Corporation","startDate":"2019-03","conditions":"Risk Reduction","enrollment":648},{"nctId":"NCT01002547","phase":"PHASE4","title":"Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2010-06-24","conditions":"Nonalcoholic Steatohepatitis","enrollment":105},{"nctId":"NCT01697592","phase":"PHASE3","title":"Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-24","conditions":"Type 2 Diabetes Mellitus","enrollment":585},{"nctId":"NCT01217073","phase":"PHASE2","title":"A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-10-08","conditions":"Type 2 Diabetes Mellitus","enrollment":685},{"nctId":"NCT01431521","phase":"PHASE1","title":"Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-10-26","conditions":"Non-alcoholic Fatty Liver Disease","enrollment":31},{"nctId":"NCT00770367","phase":"PHASE4","title":"Pioglitazone and Serum Asymmetric Dimethylarginine (ADMA) in Patients With Diabetes","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2008-10","conditions":"Diabetes","enrollment":36},{"nctId":"NCT02585765","phase":"PHASE2","title":"Skin Blood Flow Response to Insulin Iontophoresis in Pressure Ulcers of SCI","status":"WITHDRAWN","sponsor":"James J. Peters Veterans Affairs Medical Center","startDate":"2017-02-01","conditions":"Spinal Cord Injury, Pressure Ulcers","enrollment":""},{"nctId":"NCT03335956","phase":"PHASE1","title":"CORT125281 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)","status":"COMPLETED","sponsor":"Corcept Therapeutics","startDate":"2017-09-21","conditions":"Healthy","enrollment":48},{"nctId":"NCT02774343","phase":"PHASE1, PHASE2","title":"PPARγ Agonist Treatment for Cocaine Dependence","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2012-08","conditions":"Cocaine Use Disorder, Alcohol Use Disorder","enrollment":30},{"nctId":"NCT00063622","phase":"PHASE3","title":"Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS)","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2005-01","conditions":"Liver Diseases","enrollment":247},{"nctId":"NCT00782795","phase":"PHASE2","title":"Chronic Pancreatitis. Effect of Pioglitazone on Endocrine Function, Exocrine Function & Structure, Pain & Life Quality","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2008-11","conditions":"Chronic Pancreatitis, Insulin Resistance, Normal or Mildly Abnormal Stool Fat Levels","enrollment":64},{"nctId":"NCT00855010","phase":"NA","title":"Pioglitazone on Pancreatic Steatosis and Bone Health","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2009-02","conditions":"Obesity, Type 2 Diabetes","enrollment":42},{"nctId":"NCT00500331","phase":"PHASE2","title":"Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-01-23","conditions":"Diabetes Mellitus, Type 2","enrollment":334},{"nctId":"NCT01095666","phase":"PHASE3","title":"A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-06","conditions":"Type 2 Diabetes","enrollment":1484},{"nctId":"NCT00994175","phase":"PHASE2","title":"A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Severe, Refractory Asthma","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2009-09-23","conditions":"Severe, Refractory Asthma, Airway Inflammation, Airflow Obstruction","enrollment":15},{"nctId":"NCT00300365","phase":"PHASE2","title":"Pioglitazone vs Placebo in Combination With Niacin Extended Release on Low HDL","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2005-11","conditions":"Metabolic Syndrome","enrollment":38},{"nctId":"NCT00634036","phase":"PHASE2","title":"Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics","status":"COMPLETED","sponsor":"Fernando Holguin","startDate":"2009-10","conditions":"Asthma","enrollment":23},{"nctId":"NCT01395797","phase":"PHASE1, PHASE2","title":"Pioglitazone for Heroin and for Nicotine Dependence","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2011-03","conditions":"Heroin Dependence, Nicotine Dependence","enrollment":82},{"nctId":"NCT00604578","phase":"PHASE2","title":"Pioglitazone Hydrochloride (Actos(Registered Trademark)) to Treat Asthma","status":"WITHDRAWN","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2008-01-04","conditions":"Asthma, Airway Inflammation, Airflow Obstruction","enrollment":""},{"nctId":"NCT00789750","phase":"PHASE3","title":"Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2009-04","conditions":"Type 2 Diabetes Mellitus","enrollment":562},{"nctId":"NCT03196362","phase":"PHASE4","title":"Impacts of PIO/MET Following Short-term Intensive Insulin Treatment in Newly Diagnosed Type 2 Diabetes","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2016-12-01","conditions":"Type 2 Diabetes Mellitus","enrollment":50},{"nctId":"NCT01076075","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-03","conditions":"Type 2 Diabetes Mellitus","enrollment":427},{"nctId":"NCT00885352","phase":"PHASE3","title":"Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04-15","conditions":"Type 2 Diabetes Mellitus","enrollment":313},{"nctId":"NCT00722371","phase":"PHASE3","title":"MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-09-05","conditions":"Type 2 Diabetes Mellitus","enrollment":1615},{"nctId":"NCT01028391","phase":"PHASE3","title":"30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-09-01","conditions":"Type 2 Diabetes Mellitus","enrollment":317},{"nctId":"NCT00541450","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-01-15","conditions":"Type 2 Diabetes Mellitus","enrollment":492},{"nctId":"NCT00511108","phase":"PHASE1","title":"Sitagliptin and Pioglitazone Mechanism of Action Study in Type 2 Diabetes Mellitus (0431-061)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07-11","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":211},{"nctId":"NCT00397631","phase":"PHASE3","title":"Initial Combination With Pioglitazone Study (0431-064)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-12-19","conditions":"Type 2 Diabetes Mellitus","enrollment":520},{"nctId":"NCT01559857","phase":"PHASE4","title":"Pioglitazone in Patients With Mood Disorders","status":"COMPLETED","sponsor":"Stanford University","startDate":"2011-11","conditions":"Major Depressive Disorder, Insulin Resistance","enrollment":37},{"nctId":"NCT00086515","phase":"PHASE3","title":"Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-06-30","conditions":"Diabetes Mellitus, Type II","enrollment":701},{"nctId":"NCT00879970","phase":"PHASE4","title":"Thiazolidinedione Intervention With Vitamin D Evaluation","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2009-05","conditions":"Diabetes Mellitus, Type 2","enrollment":1332},{"nctId":"NCT01798706","phase":"PHASE3","title":"Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-06","conditions":"Type 2 Diabetes","enrollment":350}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo of Pioglitazone","genericName":"Placebo of Pioglitazone","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo control arm in a clinical trial and contains no active pharmaceutical ingredient. Used for Control arm in Phase 3 clinical trial of pioglitazone (indication dependent on parent trial).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}